Benzinga | Jun 14, 2021 06:35AM EDT

SVB Leerink Maintains Market Perform on Vertex Pharmaceuticals, Lowers Price Target to $200

SVB Leerink analyst Geoffrey Porges maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Market Perform and lowers the price target from $250 to $200.